Hansoh Pharma gains approval for two cancer drug trials

Hansoh Pharmaceutical Group Company Limited (HKEX:3692) announced that it has received clinical trial approvals from China's National Medical Products Administration (NMPA) for two investigational drugs, HS-20122 and HS-20108, aimed at treating advanced solid tumors. HS-20122, an antibody-drug conjugate (ADC), will be investigated in clinical trials for advanced solid tumors, specifically non-small cell lung cancer, head and neck squamous cell carcinoma, and colorectal cancer. Separately, the innovative drug HS-20108 for injection, self-developed by the Group, will be investigated in clinical trials for advanced solid tumors such as small cell lung cancer and neuroendocrine tumors. Hansoh leadership stated they are pleased to advance their oncology pipeline to combat tumors. The company, led by Chairlady Zhong Huijuan, emphasizes its commitment to advancing medical innovation for significant unmet medical needs.